Back to Multiple Sclerosis
NCT05658497
NCT05658497
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with Multiple Sclerosis (MS)
- You were either exposed to a medication called Diroximel Fumarate (DRF) at some point from around the time of conception through any point during your pregnancy, OR you did not take any MS disease-modifying medication during your pregnancy (confirm with trial site for details on exact timing)
- The outcome of your pregnancy is already known — for example, whether the pregnancy resulted in a loss or a live birth
Who may not be able to join:
- There are no listed reasons that would automatically prevent someone from joining this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Biogen
Registry
clinicaltrials_gov
Start date
27 October 2023
Est. completion
6 July 2032
Where this trial is recruiting
🇦🇺 Australia
🇩🇪 Germany
🇮🇪 Ireland
🇪🇸 Spain
🇨🇭 Switzerland
🇺🇸 United States
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Major Congenital Malformations (MCMs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.